Its clinical pharmacology centre facility receives one Form 483 observation
Jeevan Scientific Technology announced that the USFDA conducted an un-announced audit of the company's clinical pharmacology centre facility. The purpose of the audit was to review the BA/BE studies. The auditors started the review on 09 January 2018 and completed on 12 January 2018. The audit was completed with one study specific observation (Form 483).Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
